Evolent (EVH) Q1 2026 earnings review
The J-Curve Arrives: Margins Compress as Platform Lives Decline
Evolent's Q1 results delivered exactly the 'J-curve' shock management previously warned about. While revenue showed a stable, modest 2.6% YoY growth to $496.2M, Adjusted EBITDA collapsed 40% YoY to $22.1M. This severe profit compression was driven by a massive spike in the Medical Expense Ratio (MER) to 93.3%, reflecting management's conservative reserving strategy ahead of large impending contract launches. Digging deeper into the metrics reveals a mixed reality: actual lives on the platform declined across every single segment sequentially and YoY. The revenue growth was entirely salvaged by a sharp acceleration in Performance Suite pricing (PMPM), which jumped 14% YoY. The bull thesis now relies entirely on flawless execution of the impending Q3 launches to reverse the margin deterioration.
🐂 Bull Case
The company announced significant new deals, including a >$200 million annual expansion with a national payer for Oncology and Cardiology, and a new 4.5 million life advanced imaging contract. These Q3 launches provide a clear line of sight to the $2.5B FY26 revenue target.
Despite losing lives on the platform, Performance Suite revenue still grew nearly 7% YoY ($323.3M vs $303.0M). Evolent was able to successfully realize significant PMPM price increases, proving the underlying value of their specialty management to payers.
🐻 Bear Case
The company lost roughly 400K Performance Suite lives and 1M Tech & Services lives YoY. If pricing power hits a ceiling, this volume bleed will directly compress future revenue growth.
With MER spiking to 93.3%, the company is heavily reliant on driving down costs within newly launched, highly structured contracts. If actual clinical trends in these new cohorts exceed the already conservative 103% target models, H2 EBITDA will critically miss guidance.
⚖️ Verdict: ⚪
Neutral. Management successfully reset expectations last quarter, and Q1 numbers landed slightly above their projected $20M EBITDA trough. However, declining platform lives and negative operating cash flow mean Evolent has no margin for error heading into a massive H2 execution ramp.
Key Themes
Volume Contraction: Lives on Platform Declining
Reversing trend. While management frequently highlights massive market demand, the raw data contradicts the growth narrative. Average Unique Members fell from 40.6M in 25Q1 (and 40.0M in 25Q4) to 38.9M in 26Q1. The Performance Suite lost ~400K lives YoY, and the Specialty Tech & Services suite lost ~1M lives. This shrinkage places an unsustainable burden on pricing increases to drive top-line growth.
Pricing Power: Surging PMPM Fees
Accelerating. The primary driver of Q1's revenue beat was a significant expansion in Performance Suite pricing. Average PMPM fees jumped from $15.57 in 25Q1 to $17.73 in 26Q1 (a 14% YoY increase). This sequential leap from 25Q4's $13.87 PMPM successfully insulated the top line from the decline in managed lives and validates Evolent's 'enhanced' contract model economics.
J-Curve Reality: Medical Expense Ratio (MER) Spike
Reversing. As explicitly warned in the previous quarter, the MER spiked aggressively to 93.3% (up from 84.0% ex-ECP in 25Q1). This is heavily driven by conservative IBNR reserving logic applied to the massive new contract cohorts. Because MER directly determines the Performance Suite's gross margin, EBITDA cannot recover until these contracts season and actual clinical efficiencies pull the MER down toward the 7-10% long-term target margin.
Pipeline Conversion Secures H2 Ramp
Accelerating. Evolent successfully converted a national payer client for a massive expansion of existing Oncology and Cardiology solutions into new Commercial and Medicare markets. Expected to generate >$200M in annual revenue starting Q3. This confirms management's narrative that while the H1 'J-curve' is painful, the delayed revenue payload is secure and booked.
Macro: Exchange Disenrollment Hangover
Stable but negative. The structural membership losses in the ACA exchanges (previously referenced as the 'One Big Beautiful Bill' impact) continue to cause systemic drags on overall lives. Management's previous estimate of a $40M contribution hit remains a central factor constraining H1 2026 profitability.
AI & Automation Efficiency Goals
Stable. The company remains highly focused on extending market leadership in AI (specifically the 'AuthIntel' suite). Management reaffirmed commitments to utilizing AI to strip out manual review costs, which acts as a crucial offset to the near-term MER spikes by reducing fixed SG&A requirements. Adjusted SG&A successfully dropped by $4M YoY to $62.2M.
Cash Flow Reverses to Negative
Reversing. Net cash from operating activities flipped to negative $(1.0)M, down from +$4.6M in the prior year. This was heavily driven by a $21M cash burn from declining accrued liabilities and delayed collections. With leverage already elevated (net long-term debt sits at $973.5M), prolonged negative cash flow will hamper their stated goal of aggressive deleveraging.
Other KPIs
Decelerating. Dropped 2.4% from $82.8M a year ago. While the Performance Suite gets the headlines, this high-margin, fee-based segment is quietly eroding. PMPM dropped slightly to $0.35 from $0.36.
Stable improvement. Declined 6% YoY from $66.3M. This validates management's cost control and AI automation initiatives, proving they can extract back-office leverage even as total revenues climb.
Guidance
Accelerating. The midpoint of $2.5B implies a massive acceleration compared to Q1's modest 2.6% YoY growth. With Q1 printing $496M, the company must average ~$668M per quarter for the rest of the year. This hockey-stick ramp is wholly dependent on the on-time, seamless Q3 launches of the Highmark, Aetna, and new national payer expansions.
Decelerating relative to historical baseline, but implies an internal acceleration. Given Q1 delivered just $22.1M, hitting the $125M midpoint requires sequential acceleration across Q2-Q4. Management is betting heavily that the currently inflated 93.3% MER will normalize downward in the back half of the year as new contracts season.
Stable. Reiterated guidance for internal cash deployment toward software, supporting the ongoing Machinify/AI clinical integration efforts.
Key Questions
Platform Lives Leakage
Performance Suite lives dropped 6% sequentially and Tech & Services dropped 4%. How much of this was proactive culling of unprofitable contracts versus unregretted exchange churn, and when do we see sequential net additions?
PMPM Ceiling
Performance Suite PMPM jumped 14% YoY to $17.73. Is this a permanent structural step-up due to case mix, or the ceiling of your pricing power with current plan partners?
MER Maturation Velocity
With the MER spiking to 93.3% driven by conservative reserving, what specific leading claims indicators will you need to see in Q2 to safely begin releasing those reserves and inflecting the EBITDA J-curve upward?
Operating Cash Flow Trajectory
OCF turned negative in Q1 due to working capital drags. Given the massive implementations slated for Q3, when should investors expect free cash flow to comfortably support your deleveraging targets?